We are live on ! Find out more
XLRN

Acceleron Pharma
XLRN

Delisted

XLRN was delisted on the 19th of November, 2021.

Back to rankings

1 hedge funds and large institutions have $0 invested in Acceleron Pharma in 2021 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 325 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 330 → 1 (-329)

100% less funds holding in top 10

Funds holding in top 10: 13 → 0 (-13)

100% less capital invested

Capital invested by funds: $9.13B → $0 (-$9.13B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 325

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
1
Holders Change
-329
Holders Change %
-99.7%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
-13
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
325
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$923M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$848M
3
ACA
Avoro Capital Advisors
New York
-$688M
4
BlackRock
BlackRock
New York
-$684M
5
FCM
Farallon Capital Management
California
-$373M
Name Holding Trade Value Shares
Change 		Change in
Stake
VOYA Investment Management
151
VOYA Investment Management
Georgia
– -$2.87M -16,670 Closed
SMC
152
S. Muoio & Co
New York
– -$2.58M -15,000 Closed
ASRS
153
Arizona State Retirement System
Arizona
– -$2.56M -14,881 Closed
PAMS
154
Pictet Asset Management (Switzerland)
Switzerland
– -$2.54M -14,765 Closed
ProShare Advisors
155
ProShare Advisors
Maryland
– -$2.46M -14,285 Closed
BCI
156
Brinker Capital Investments
Pennsylvania
– -$1.79M -14,239 Closed
HA
157
Havens Advisors
New York
– -$2.41M -14,000 Closed
PIM
158
Platinum Investment Management
Australia
– -$2.39M -13,872 Closed
Squarepoint
159
Squarepoint
New York
– -$2.27M -13,193 Closed
FCM
160
Frontier Capital Management
Massachusetts
– -$2.24M -13,030 Closed
KAS
161
Kestra Advisory Services
Texas
– -$2.18M -12,654 Closed
JRP
162
Jasper Ridge Partners
California
– -$2.15M -12,498 Closed
Marshall Wace
163
Marshall Wace
United Kingdom
– -$2.08M -12,096 Closed
AAM
164
Advisors Asset Management
Colorado
– -$2.08M -12,073 Closed
BPA
165
Beacon Pointe Advisors
California
– -$2.02M -11,763 Closed
RJA
166
Raymond James & Associates
Florida
– -$1.95M -11,314 Closed
SG Americas Securities
167
SG Americas Securities
New York
– -$1.88M -10,909 Closed
BC
168
Birchview Capital
Vermont
– -$1.84M -10,672 Closed
TAL
169
TIG Advisors LLC
New York
– -$1.72M -10,003 Closed
CC
170
Centiva Capital
New York
– -$1.72M -10,000 Closed
MCM
171
Mason Capital Management
New York
– -$1.72M -10,000 Closed
NSEDCP
172
NJ State Employees Deferred Compensation Plan
New Jersey
– -$1.72M -10,000 Closed
AGM
173
Alpine Global Management
New York
– -$1.69M -9,846 Closed
HS
174
HighVista Strategies
Massachusetts
– -$1.68M -9,777 Closed
AB
175
Amalgamated Bank
New York
– -$1.64M -9,554 Closed
5 6
7
8 9

XLRN Hedge Fund Activity: Q4 2021 in Review

1 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q4 2021, worth a combined $0 — down 100% from $9.13B a quarter earlier.

Sellers outnumbered buyers: 325 funds closed out of XLRN and 0 opened new positions — a net loss of 325 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $923M sold.

  • 1 institutional investor held Acceleron Pharma (XLRN) as of Q4 2021, down from 330 in Q3 2021.
  • Funds reported $0 of Acceleron Pharma stock for Q4 2021, down 100% quarter-over-quarter.
  • 0 funds opened new Acceleron Pharma positions in Q4 2021 and 325 closed out, a net change of -325 holders.
  • The largest Acceleron Pharma seller in Q4 2021 was T. Rowe Price Associates, an estimated $923M sold.

Based on aggregated 13F filings for Q4 2021.